Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 8/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.45 |
| ▸ | WEE1 | P30291 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 3/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.39 |
| ▸ | CDK9 | P50750 | 3/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24277131 | 1.00 | HASPIN (0.50) | HASPINMAPTBCHEACHETOP2A | |
| SCHEMBL24277018 | 0.82 | NPY5R (0.44) | HASPINMAPTWEE1PIM1CCNT1 | |
| SCHEMBL29445149 | 0.82 | HASPIN (0.44) | HASPINMAPTWEE1PIM1CCNT1 | |
| SCHEMBL24277029 | 0.82 | HASPIN (0.44) | HASPINMAPTWEE1PIM1CCNT1 | |
| SCHEMBL24277130 | 0.81 | MAPT (0.55) | HASPINMAPTBCHEACHETOP2A | |
| SCHEMBL29445106 | 0.79 | TOP2A (0.48) | HASPINMAPTBCHEACHETOP2A | |
| SCHEMBL24277244 | 0.79 | TOP2A (0.48) | HASPINMAPTBCHEACHETOP2A | |
| SCHEMBL24276806 | 0.78 | BCHE (0.45) | HASPINMAPTBCHEACHETOP2A | |
| SCHEMBL11808516 | 0.77 | BCHE (0.67) | MAPTBCHEACHEWEE1ALOX5 | |
| SCHEMBL24277232 | 0.75 | HASPIN (0.41) | HASPINMAPTBCHEACHETOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4210703-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | Expansion Therapeutics, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022055922-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | EXPANSION THERAPEUTICS, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | FUS, SNRPE, RRBP1 | HASPIN 2918/4885MAPT 349/4885BCHE 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.